Difference between revisions of "Team:New York City/Human Practices"

Line 3: Line 3:
 
<head>
 
<head>
 
     <link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.1.3/css/bootstrap.min.css" integrity="sha384-MCw98/SFnGE8fJT3GXwEOngsV7Zt27NXFoaoApmYm81iuXoPkFOJwJ8ERdknLPMO" crossorigin="anonymous">
 
     <link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.1.3/css/bootstrap.min.css" integrity="sha384-MCw98/SFnGE8fJT3GXwEOngsV7Zt27NXFoaoApmYm81iuXoPkFOJwJ8ERdknLPMO" crossorigin="anonymous">
 +
    <link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.3.1/css/brands.css" integrity="sha384-rf1bqOAj3+pw6NqYrtaE1/4Se2NBwkIfeYbsFdtiR6TQz0acWiwJbv1IM/Nt/ite" crossorigin="anonymous">
 +
    <link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.3.1/css/fontawesome.css" integrity="sha384-1rquJLNOM3ijoueaaeS5m+McXPJCGdr5HcA03/VHXxcp2kX2sUrQDmFc3jR5i/C7" crossorigin="anonymous">
 
     <style>
 
     <style>
 
         .container {
 
         .container {
Line 71: Line 73:
  
 
<div class="container py-0 align-middle">
 
<div class="container py-0 align-middle">
−
     <h2 align="center">Integrated Practices</h2>
+
     <h2 align="center">Human Practices</h2>
 
</div>
 
</div>
  
 
<div class="container">
 
<div class="container">
−
     <p class="lead">Our team originally focused on developing a modified RNA protein replacement technology for Huntington’s under the guise that the Huntington’s phenotype was caused by the loss of function of the Huntingtin protein due to polyglutame repeats. During our continued research thought the project, we discovered that there are 2 copies of HTT and simply up regulating the good copy as long as disease state HTT protein is present. Thus we decided it may be better to change the focus of our project from validating toe-hold displacement to expression of human endogenous HTT mRNA so that others could use it do develop RNAi style therapies. However, after we collaborated with the Huntington’s Disease Society of America, we discovered that the current research in treatment both targeted the endogenous and normal RNA strands, essentially stopping the production of all Huntington protein. Thus, our team is once again focused on validating toehold exchange to affect HTT to replace the mRNA targeted by RNAi with a corrected synthetic mRNA.</p>
+
     <p class="lead">Our team originally focused on developing a modified RNA protein replacement technology for
 +
        Huntington's under the guise that the Huntington's phenotype was caused by the loss of function of the
 +
        Huntingtin protein due to polyglutame repeats. During our continued research thought the project, we
 +
        discovered that there are 2 copies of HTT and simply up regulating the good copy as long as disease state
 +
        HTT protein is present. Thus we decided it may be better to change the focus of our project from validating
 +
        toe-hold displacement to expression of human endogenous HTT mRNA so that others could use it do develop RNAi
 +
        style therapies. However, after we collaborated with the Huntington's Disease Society of America, we discovered
 +
        that the current research in treatment both targeted the endogenous and normal RNA strands, essentially
 +
        stopping the production of all Huntington protein. Thus, our team is once again focused on validating
 +
        toehold exchange to affect HTT to replace the mRNA targeted by RNAi with a corrected synthetic mRNA.</p>
 +
</div>
 +
<br/>
 +
<div class="container" align="center">
 +
    <div class="row" align="center">
 +
        <div class="col-sm-3">
 +
        </div>
 +
        <div class="col-sm-2">
 +
            <a href="https://www.facebook.com/HDResolution/"><i class="fab fa-facebook-f display-4"></i></a>
 +
        </div>
 +
        <div class="col-sm-2">
 +
            <a href="https://twitter.com/HDNYC_iGEM"><i class="fab fa-twitter display-4"></i></a>
 +
        </div>
 +
        <div class="col-sm-2">
 +
            <a href="https://www.instagram.com/nyc_igem/"><i class="fab fa-instagram display-4"></i></a>
 +
        </div>
 +
        <div class="col-sm-3">
 +
        </div>
 +
    </div>
 +
    <br/>
 
</div>
 
</div>
−
 
 
<script src="https://code.jquery.com/jquery-3.3.1.slim.min.js" integrity="sha384-q8i/X+965DzO0rT7abK41JStQIAqVgRVzpbzo5smXKp4YfRvH+8abtTE1Pi6jizo" crossorigin="anonymous"></script>
 
<script src="https://code.jquery.com/jquery-3.3.1.slim.min.js" integrity="sha384-q8i/X+965DzO0rT7abK41JStQIAqVgRVzpbzo5smXKp4YfRvH+8abtTE1Pi6jizo" crossorigin="anonymous"></script>
 
<script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.14.3/umd/popper.min.js" integrity="sha384-ZMP7rVo3mIykV+2+9J3UJ46jBk0WLaUAdn689aCwoqbBJiSnjAK/l8WvCWPIPm49" crossorigin="anonymous"></script>
 
<script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.14.3/umd/popper.min.js" integrity="sha384-ZMP7rVo3mIykV+2+9J3UJ46jBk0WLaUAdn689aCwoqbBJiSnjAK/l8WvCWPIPm49" crossorigin="anonymous"></script>

Revision as of 04:13, 17 September 2018

Human Practices

Our team originally focused on developing a modified RNA protein replacement technology for Huntington's under the guise that the Huntington's phenotype was caused by the loss of function of the Huntingtin protein due to polyglutame repeats. During our continued research thought the project, we discovered that there are 2 copies of HTT and simply up regulating the good copy as long as disease state HTT protein is present. Thus we decided it may be better to change the focus of our project from validating toe-hold displacement to expression of human endogenous HTT mRNA so that others could use it do develop RNAi style therapies. However, after we collaborated with the Huntington's Disease Society of America, we discovered that the current research in treatment both targeted the endogenous and normal RNA strands, essentially stopping the production of all Huntington protein. Thus, our team is once again focused on validating toehold exchange to affect HTT to replace the mRNA targeted by RNAi with a corrected synthetic mRNA.